Reversal of skeletal resistance to parathyroid hormone in uremia by vitamin D metabolites: evidence for the requirement of 1,25(OH)2D3 and 24,25(OH)2D3
- PMID: 469372
Reversal of skeletal resistance to parathyroid hormone in uremia by vitamin D metabolites: evidence for the requirement of 1,25(OH)2D3 and 24,25(OH)2D3
Abstract
This study evaluates the role of vitamin D metabolites in the genesis of the skeletal resistance to the calcemic action of PTH in uremia. The changes in serum calcium after infusion of 2 U of PTE per kilogram per hour for 8 hr were evaluated in thyroparathyroidectomized dogs before and after 1 and 3 days of acute uremia produced by bilateral nephrectomy. The animals received vitamin D metabolites during the 3 days of uremia. Supplementation of 0.68 microgram/day 1,25(OH)2D3 and 24R,25(OH)2D3 restored the calcemic response to PTE to normal. This is in contrast to only partial correction of the response to PTE by 1,25(OH)2D3 alone. Administration of 1.36 microgram/day 24R,25(OH)2D3 did not improve the calcemic response to PTE. The results indicate that (1) both 1,25(OH)2D3 and 24R,25(OH)2D3 are necessary for the complete reversal of the impaired calcemic response to PTE, (2) this effect is not due to the increase in the amount of the dihydroxylated compounds of vitamin D, since equivalent amounts of these compounds in the form of 24R,25(OH)2D3 alone had no effect, and (3) the better effect of the combination of 1,25(OH)2D3 and 24R,25(OH)2D3 is most probably due to an interaction between these two metabolites of vitamin D permitting an intact calcemic action of PTH.
Similar articles
-
Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25 (OH)2 D3.Kidney Int. 1976 Jun;9(6):467-74. doi: 10.1038/ki.1976.60. Kidney Int. 1976. PMID: 940279
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.Miner Electrolyte Metab. 1985;11(6):358-68. Miner Electrolyte Metab. 1985. PMID: 3877862
-
Effect of parathyroid hormone and uremia on peripheral nerve calcium and motor nerve conduction velocity.J Clin Invest. 1978 Jul;62(1):88-93. doi: 10.1172/JCI109118. J Clin Invest. 1978. PMID: 659642 Free PMC article.
-
[Vitamin D metabolism in kidney insufficiency: disorders of an endocrine regulatory zone].Klin Wochenschr. 1979 Oct 1;57(19):1053-9. doi: 10.1007/BF01479991. Klin Wochenschr. 1979. PMID: 392179 Review. German.
Cited by
-
Vitamin D3 analogs and salmon calcitonin partially reverse the development of renal osteodystrophy in rats.Calcif Tissue Int. 1995 Nov;57(5):385-91. doi: 10.1007/BF00302075. Calcif Tissue Int. 1995. PMID: 8564802
-
Short-term effects of vitamin D3 and 1,25-dihydroxyvitamin D3 on osteomalacia in uremic rats fed a low calcium-low-phosphorus diet.Am J Pathol. 1981 Jul;104(1):35-40. Am J Pathol. 1981. PMID: 6266257 Free PMC article.
-
Interaction between 24R,25-dihydroxycholecalciferol and 1,25-dihydroxycholecalciferol on 45Ca release from bone in vitro.Calcif Tissue Int. 1981;33(6):663-6. doi: 10.1007/BF02409505. Calcif Tissue Int. 1981. PMID: 6799176
-
Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.J Clin Invest. 1986 Oct;78(4):1097-102. doi: 10.1172/JCI112666. J Clin Invest. 1986. PMID: 3760186 Free PMC article.
-
Relative effectiveness of vitamin D metabolites in increasing bone mineral solubility.Calcif Tissue Int. 1981;33(2):159-65. doi: 10.1007/BF02409429. Calcif Tissue Int. 1981. PMID: 6783272